Amifampridine
Potassium Channel Blocker — NERVOUS SYSTEM
Also known as: 3,4-DAP, amifampridin, amifampridine phosphate, DAP, firdapse
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Amifampridine is an ofp drug in the Potassium Channel Blocker class catalogued in DrugCentral. It was first approved by the EMA in 2009. Its mechanism of action is classified as Potassium Channel Antagonists. DrugCentral lists 1 molecular target, including KCNQ3|KCNQ2|KCNH1|KCNA2|KCNA6|KCNA3|KCNA4|KCNA5|KCNC1|KCNQ1|KCNQ4|KCNC4|KCNA1|KCNH2|KCNC3|KCNB1|KCNA10|KCNV1|KCNH5|KCNG3|KCNG4|KCNV2|KCNB2|KCNS1|KCNH8|KCNC2|KCNA7|KCNS3|KCNH6|KCNF1|KCNQ5|KCNH7|KCND1|KCND2|KCNG1|KCNG2|KCND3|KCNH3|KCNS2|KCNH4. Recorded indications include Eaton-Lambert syndrome.
- Approval status: ofp (first approved 2009 by the EMA).
- Drug class: Potassium Channel Blocker.
- Mechanism of action: Potassium Channel Antagonists.
- Molecular targets: KCNQ3|KCNQ2|KCNH1|KCNA2|KCNA6|KCNA3|KCNA4|KCNA5|KCNC1|KCNQ1|KCNQ4|KCNC4|KCNA1|KCNH2|KCNC3|KCNB1|KCNA10|KCNV1|KCNH5|KCNG3|KCNG4|KCNV2|KCNB2|KCNS1|KCNH8|KCNC2|KCNA7|KCNS3|KCNH6|KCNF1|KCNQ5|KCNH7|KCND1|KCND2|KCNG1|KCNG2|KCND3|KCNH3|KCNS2|KCNH4 (1 listed in DrugCentral).
- Indications: Eaton-Lambert syndrome.
- ATC code: N07XX05 (Other nervous system drugs).
- Molecular formula: C5H7N3; molecular weight 109.13 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Eaton-Lambert syndrome
Mechanism & targets
| Mechanism of action (MoA) | Potassium Channel Antagonists |
|---|---|
| Established pharmacologic class | Potassium Channel Blocker |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Voltage-gated potassium channel | KCNQ3|KCNQ2|KCNH1|KCNA2|KCNA6|KCNA3|KCNA4|KCNA5|KCNC1|KCNQ1|KCNQ4|KCNC4|KCNA1|KCNH2|KCNC3|KCNB1|KCNA10|KCNV1|KCNH5|KCNG3|KCNG4|KCNV2|KCNB2|KCNS1|KCNH8|KCNC2|KCNA7|KCNS3|KCNH6|KCNF1|KCNQ5|KCNH7|KCND1|KCND2|KCNG1|KCNG2|KCND3|KCNH3|KCNS2|KCNH4 | blocker | — |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2018-11-28 | FDA | — | CATALYST PHARMS | Yes |
| 2009-12-23 | EMA | — | BioMarin Europe Ltd | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N07XX05 | NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › OTHER NERVOUS SYSTEM DRUGS › Other nervous system drugs |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- EMA label
- FDA label: NAT2 · Actionable PGx
- HCSC label: NAT2 · Actionable PGx
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Myasthenia gravis crisis | 42.1 |
| Asthenia | 34.4 |
| Paraesthesia oral | 31.1 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Amifampridine is on its molecule page.
| Molecular formula | C5H7N3 |
|---|---|
| Molecular weight | 109.13 g/mol |
| CAS number | 54-96-6 |
| InChIKey | OYTKINVCDFNREN-UHFFFAOYSA-N |
| PubChem CID | 5918 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Amifampridine used for?
DrugCentral lists the following indications for Amifampridine: Eaton-Lambert syndrome.
How does Amifampridine work?
Amifampridine is classified as Potassium Channel Antagonists; its molecular targets in DrugCentral include KCNQ3|KCNQ2|KCNH1|KCNA2|KCNA6|KCNA3|KCNA4|KCNA5|KCNC1|KCNQ1|KCNQ4|KCNC4|KCNA1|KCNH2|KCNC3|KCNB1|KCNA10|KCNV1|KCNH5|KCNG3|KCNG4|KCNV2|KCNB2|KCNS1|KCNH8|KCNC2|KCNA7|KCNS3|KCNH6|KCNF1|KCNQ5|KCNH7|KCND1|KCND2|KCNG1|KCNG2|KCND3|KCNH3|KCNS2|KCNH4 (blocker).
When was Amifampridine first approved?
Amifampridine was first approved by the EMA in 2009.
What drug class does Amifampridine belong to?
Amifampridine is in the Potassium Channel Blocker class.
What is the chemical formula of Amifampridine?
Amifampridine has the molecular formula C5H7N3 and a molecular weight of 109.13 g/mol.
Browse: all drugs starting with A · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4336 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3301611 — compound record and bioactivity
- PubChem CID 5918 — chemical identifiers
- DrugBank DB11640 — drug record
- FDA UNII RU4S6E2G0J — substance identity
- DailyMed: FDA labels for Amifampridine — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.